Amarantus Diagnostics: $300,000,000 In Revenue In Two Year?
Amarantus BioScience, Inc. (AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, has appointed Adam J. Simon, Ph.D., to its Board of Advisors. Dr. Simon is a world expert in the field of Alzheimer’s disease biomarkers and has significant expertise in the development of in-vitro diagnostics.
“Dr. Simon will play an important role in the development of our LymPro diagnostic blood test for Alzheimer’s disease,” said Gerald E. Commissiong, President and Chief Executive Officer of Amarantus BioScience. “He is a recognized leader in the discovery of Alzheimer’s biomarkers, and has advised both major pharmaceutical companies and early stage research companies on their clinical programs and regulatory submissions. Dr. Simon is also an entrepreneur in his own right, and understands the specific challenges and opportunities we face here at Amarantus.”
Dr. Simon is the founder and president of AJ Simon Enterprises, LLC, a consulting firm serving pharmaceutical and biotechnology clients, including Bristol Myers Squibb. He is also the founder and chief executive officer of Cerora, Inc., a healthcare information technology company focused on developing medical devices and services to assess brain health, including Traumatic Brain Injury. Earlier in his career he spent more than 13 years at Merck Research Laboratories, where he served as a Senior Research Fellow in Integrative Systems Neuroscience and Biomarkers and in Alzheimer’s disease research. He has also been a visiting scientist at Princeton University.
Dr. Simon received Bachelor’s degrees in Physics and Mathematics from the University of Rochester. He received a Doctorate in Physics from the University of Chicago. He holds four patents related to medical research, and has published more than 60 articles in scientific and medical journals.